Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001
Authors:
- Kelly A. GeboKGKelly A. Gebo
- John A. FleishmanJFJohn A. Fleishman
- Richard ConviserRCRichard Conviser
- Erin D. ReillyERErin D. Reilly
- P. Todd KorthuisPKP. Todd Korthuis
- Richard D. MooreRMRichard D. Moore
- James HellingerJHJames Hellinger
- Philip KeiserPKPhilip Keiser
- Haya R. RubinHRHaya R. Rubin
- Lawrence CraneLCLawrence Crane
- Fred J. HellingerFHFred J. Hellinger
- W. Christopher MathewsWMW. Christopher Mathews
- 1 January 2005
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 38 (1) , 96-103
Abstract
National data from the mid-1990s demonstrated that many eligible patients did not receive highly active antiretroviral therapy (HAART) and that racial and gender disparities existed in HAART receipt. We examined whether demographic disparities in the use of HAART persist in 2001 and if outpatient care is associated with HAART utilization. Demographic, clinical, and pharmacy utilization data were collected from 10 US HIV primary care sites in the HIV Research Network (HIVRN). Using multivariate logistic regression, we examined demographic and clinical differences associated with receipt of HAART and the association of outpatient utilization with HAART. In our cohort in 2001, 84% of patients received HAART and 66% had 4 or more outpatient visits during calendar year (CY) 2001. Of those with 2 or more CD4 counts below 350 cells/mm3 in 2001, 91% received HAART; 82% of those with 1 CD4 test result below 350 cells/mm3 received HAART; and 77% of those with no CD4 counts below 350 cells/mm3 received HAART. Adjusting for care site in multivariate analyses, age >40 years (adjusted odds ratio [AOR] = 1.13), male gender (AOR = 1.23), Medicaid coverage (AOR = 1.16), Medicare coverage (AOR = 1.73), having 1 or more CD4 counts less than 350 cells/mm3 (AOR = 1.33), and having 4 or more outpatient visits in a year (OR = 1.34) were significantly associated with an increased likelihood of HAART. African Americans (odds ratio [OR] = 0.84) and those with an injection drug use risk factor (OR = 0.86) were less likely to receive HAART. Although the overall prevalence of HAART has increased since the mid-1990s, demographic disparities in HAART receipt persist. Our results support attempts to increase access to care and frequency of outpatient visits for underutilizing groups as well as increased efforts to reduce persistent disparities in women, African Americans, and injection drug users (IDUs).Keywords
This publication has 39 references indexed in Scilit:
- Racial Disparity in Influenza VaccinationJAMA, 2001
- Racial Differences in the Use of Invasive Cardiovascular Procedures: Review of the Literature and Prescription for Future ResearchAnnals of Internal Medicine, 2001
- Reducing racial disparities in transplant activation:Whom should we target?American Journal of Kidney Diseases, 2001
- AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral TherapyJAMA, 1999
- Natural history of HIV infection in the_era of combination antiretroviral therapyAIDS, 1999
- The association between primary source of ambulatory care and access to a outcomes of treatment among AIDS patientsInternational Journal for Quality in Health Care, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centresAIDS, 1997
- Impact of Combination Therapy for HIV Infection on Inpatient CensusNew England Journal of Medicine, 1997
- Access to therapy in the multicenter AIDS Cohort Study, 1989–1992Journal of Clinical Epidemiology, 1994